What is the 13F Pro Quality Score for RNXT?

13F Pro ranks RenovoRx, Inc. (RNXT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RNXT's current score at https://13fpro.ai/company/RNXT (free sign-up required for the full ranking).

Where does 13F Pro source RNXT data?

All RenovoRx, Inc. fundamentals and ownership data come directly from SEC EDGAR. RenovoRx, Inc. files with the SEC under CIK 1574094. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RNXT in?

RenovoRx, Inc. (RNXT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RNXT research updated on 13F Pro?

RNXT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RenovoRx, Inc.(RNXT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1574094 RNXT stock profile & AI dashboard →

13F Pro Quality Score

26.0/100

Rank #2,639 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RNXT Scores 26/100

exact factor attribution · 2026-09-11

RNXT's composite is driven by revenue growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.1 pts

96th pct

Institutional flow

-0.3 pts

45th pct

Shareholder dilution

-2.2 pts

6th pct

Earnings growth

-2.2 pts

5th pct

Earnings quality

-3.6 pts

14th pct

Capital efficiency

-4.6 pts

4th pct

Profitability

-6.5 pts

7th pct

Free cash flow

-6.7 pts

6th pct

Scale

-7.0 pts

3th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RNXT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for RenovoRx, Inc. (RNXT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RNXT at 26.0/100 on a 32-signal composite quality model, placing it at rank #2,639 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), RenovoRx, Inc. reports quarterly revenue of $909.0K, net income of $-2.9M, free cash flow of $-2.9M. Top institutional holders of RNXT by reported 13-F value include AIGH Capital Management, Bleichroeder, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. RNXT trades on the Nasdaq exchange and files with the SEC under CIK 1574094. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNXT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RenovoRx, Inc. directly from SEC EDGAR. RenovoRx, Inc.'s 13F Pro composite quality score has ranged between 25 and 27 since 2026, currently 26.0 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about RenovoRx, Inc.

Quirks, history, and lore behind RNXT — the kind of stuff that makes a stock memorable.

1
The Basics
A micro-cap U.S. biopharmaceutical company listed on Nasdaq, headquartered in California, focused on oncology.
2
The Numbers
With a market cap in the low tens of millions and minimal revenue, this is very much a clinical-stage company — burning cash in pursuit of a breakthrough.
3
The History
The company was built around a novel approach to delivering chemotherapy directly to a tumor site, aiming to avoid the brutal systemic side effects of traditional treatment.
4
The Secret
Its core platform repurposes an existing FDA-approved catheter technology to deliver drugs locally — meaning the delivery device itself isn't new, just the targeted application.
5
The Lore
Its lead program targets locally advanced pancreatic cancer — one of oncology's most feared and hard-to-treat diagnoses — using trans-arterial micro-perfusion.
6
The Giveaway
The ticker spells out the mission: Renovo — to renew — and its RenovoGem therapy delivers gemcitabine straight to pancreatic tumors, one catheter at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$909.0K

Net Income

Q2 2026

$-2.9M

Free Cash Flow

Q2 2026

$-2.9M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+2511.6% YoY

$1.1MFY 2025

FY22 —FY23 —FY24 $43.0KFY25 $1.1M

Net Income

-26.7% YoY

$-11.2MFY 2025

FY22 $-9.9MFY23 $-10.2MFY24 $-8.8MFY25 $-11.2M

Operating Income

-14.0% YoY

$-12.5MFY 2025

FY22 $-9.9MFY23 $-11.4MFY24 $-11.0MFY25 $-12.5M

EPS (Diluted)

+20.0% YoY

$-0.32FY 2025

FY22 $-1.09FY23 $-0.99FY24 $-0.40FY25 $-0.32

Total Assets

-0.3% YoY

$8.1MFY 2025

FY22 $7.3MFY23 $1.5MFY24 $8.1MFY25 $8.1M

Op. Cash Flow

-20.3% YoY

$-11.0MFY 2025

FY22 $-8.8MFY23 $-10.3MFY24 $-9.1MFY25 $-11.0M

Free Cash Flow

-20.1% YoY

$-11.0MFY 2025

FY22 —FY23 —FY24 $-9.1MFY25 $-11.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.1M +2511.6%	$43.0K	—	—	—	—
Net Income	$-11.2M -26.7%	$-8.8M +13.9%	$-10.2M -3.5%	$-9.9M -56.4%	$-6.3M -66.5%	$-3.8M
Operating Income	$-12.5M -14.0%	$-11.0M +3.7%	$-11.4M -14.5%	$-9.9M -75.5%	$-5.7M -77.0%	$-3.2M
EPS (Diluted)	$-0.32 +20.0%	$-0.40 +59.6%	$-0.99 +9.2%	$-1.09	—	—
Total Assets	$8.1M -0.3%	$8.1M +453.8%	$1.5M -79.8%	$7.3M -55.4%	$16.3M +750.9%	$1.9M
Operating Cash Flow	$-11.0M -20.3%	$-9.1M +11.0%	$-10.3M -16.4%	$-8.8M -48.9%	$-5.9M -67.7%	$-3.5M
Free Cash Flow	$-11.0M -20.1%	$-9.1M	—	—	—	—

Get alerted when RNXT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RenovoRx, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RNXT

AIGH Capital Management LLC
$4.3M4,405,439 sh
Bleichroeder LP
$1.6M1,666,098 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.4M1,443,742 sh
GEODE CAPITAL MANAGEMENT, LLC
$415.7K424,148 sh
Wealthspire Advisors, LLC
$247.5K252,525 sh
VANGUARD FIDUCIARY TRUST CO
$235.5K240,330 sh
CITADEL ADVISORS LLC
$130.9K133,597 sh
NORTHERN TRUST CORP
$83.5K85,207 sh
Chicago Partners Investment Group LLC
$78.9K92,356 sh
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$73.1K74,596 sh

Fund	Value	Shares
AIGH Capital Management LLC	$4.3M	4,405,439
Bleichroeder LP	$1.6M	1,666,098
VANGUARD CAPITAL MANAGEMENT LLC	$1.4M	1,443,742
GEODE CAPITAL MANAGEMENT, LLC	$415.7K	424,148
Wealthspire Advisors, LLC	$247.5K	252,525
VANGUARD FIDUCIARY TRUST CO	$235.5K	240,330
CITADEL ADVISORS LLC	$130.9K	133,597
NORTHERN TRUST CORP	$83.5K	85,207
Chicago Partners Investment Group LLC	$78.9K	92,356
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	$73.1K	74,596

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RNXT on your watchlist

Track score changes the day RenovoRx, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RNXT a good stock to buy?

13F Pro's AI-powered analysis of RenovoRx, Inc. (RNXT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNXT are available on the RNXT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RNXT is classified as a small company.

Which hedge funds own RNXT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNXT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RenovoRx, Inc.'s investment landscape.